Document is current
Any future updates will be listed below
-
Authors
Kessler, Ronald C. https://orcid.org/0000-0003-4831-2305
Millikan-Bell, Amy M.
Edwards, Emily R.
Gildea, Sarah M.
King, Andrew J.
Liu, Howard https://orcid.org/0000-0002-0747-7886
Petukhova, Maria V.
Sampson, Nancy A.
Ziobrowski, Hannah N.
Wagner, James R. https://orcid.org/0000-0002-8823-3110
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Ursano, Robert J.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH087981, U01MH087981, U01MH087981, U01MH087981)
U.S. Department of Defense (HU0001-15-2-0004, HU0001-15-2-0004, HU0001-15-2-0004, HU0001-15-2-0004)
United States Department of Veterans Affairs, Clinical Sciences Research and Development Service (CSR&D) VA-STARRS Researcher-in-Residence Program
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 20 August 2025
First Online: 29 September 2025
Competing interests
: In the past 3 years, R.C.K. was a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Child Mind Institute, Holmusk, Massachusetts General Hospital, Partners Healthcare, Inc., RallyPoint Networks, Inc., Sage Therapeutics and University of North Carolina. He has stock options in Cerebral Inc., Mirah, PYM (Prepare Your Mind), Roga Sciences and Verisense Health. In the past 3 years, M.B.S. received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals and Roche/Genentech. He has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on Biological Psychiatry (Deputy Editor) and UpToDate (Co-Editor-in-Chief for Psychiatry). The other authors declare no competing interests.
